Fluorinated N-acetyl glucosamine analogs and xylose derivatives
AssigneeUTI Limited Partnership
InventorsVoon Wee Yong, Chang-Chun Ling, Erin Laurel Stephenson, Ping Zhang, Michael Bradley Keough, Khalil Sherali Rawji
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to fluorinated glucosamine analogs and uses thereof, including analogs of N-acetyl glucosamine fluorinated at 4- and/or 6-position(s) and derivatives of xylose at anomeric position for the treatment of a neurological disease, such as multiple sclerosis; inflammation; cancer; central nervous system injury; or conditions associated with up-regulation of an extracellular matrix, such as chondroitin sulfate proteoglycans.
Claims19
A compound of formula (65) or a pharmaceutically acceptable salt thereof:
- wherein R1, R2 and R3 are independently H or an acyl group and at least one of R1, R2 and R3 is an acyl group defined as R′CO— or R″XCO″, wherein:
- R′ is a substituted or unsubstituted, branched or linear alkyl or heteroalkyl containing up to 20 carbons;
- R″ is a substituted or unsubstituted, branched or linear alkyl or heteroalkyl containing up to 20 carbons;
- and
- X is a heteroatom selected from the group consisting of O, N, and S;
- and
- R1, R2, and R3 are not an acetyl group at the same time.
Dependencies are inferred from the claim text.